Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective
Top Cited Papers
Open Access
- 13 January 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 36 (19), 1163-1170
- https://doi.org/10.1093/eurheartj/ehu505
Abstract
AimsLong-term disease progression following myocardial infarction (MI) is not well understood. We examined the risk of subsequent cardiovascular events in patients discharged after MI in Sweden.Methods and resultsThis was a retrospective, cohort study linking morbidity, mortality, and medication data from Swedish national registries. Of 108 315 patients admitted to hospital with a primary MI between 1 July 2006 and 30 June 2011 (index MI), 97 254 (89.8%) were alive 1 week after discharge and included in this study. The primary composite endpoint of risk for non-fatal MI, non-fatal stroke, or cardiovascular death was estimated for the first 365 days post-index MI and Day 366 to study completion. Risk and risk factors were assessed by Kaplan–Meier analysis and Cox proportional hazards modelling, respectively. Composite endpoint risk was 18.3% during the first 365 days post-index MI. Age [60–69 vs. 80 vs. <60 years: 3.96 (3.78–4.15)], prior MI [1.44 (1.40–1.49)], stroke [1.49 (1.44–1.54)], diabetes [1.37 (1.34–1.40)], heart failure [1.57 (1.53–1.62)] and no index MI revascularisation [1.88 (1.83–1.93)] were each independently associated with a higher risk of ischaemic events or death. For patients without a combined endpoint event during the first 365 days, composite endpoint risk was 20.0% in the following 36 months.ConclusionsRisk of cardiovascular events appeared high beyond the first year post-MI, indicating a need for prolonged surveillance, particularly in patients with additional risk factors.Keywords
This publication has 27 references indexed in Scilit:
- Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trialAmerican Heart Journal, 2014
- Cardiovascular disease in Europe: epidemiological updateEuropean Heart Journal, 2013
- Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980–2009European Heart Journal, 2013
- Vorapaxar in the Secondary Prevention of Atherothrombotic EventsThe New England Journal of Medicine, 2012
- Global Variation in the Relative Burden of Stroke and Ischemic Heart DiseaseCirculation, 2011
- External review and validation of the Swedish national inpatient registerBMC Public Health, 2011
- Projections of Global Mortality and Burden of Disease from 2002 to 2030PLoS Medicine, 2006
- The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six monthsPharmacoepidemiology and Drug Safety, 2006
- Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic EventsThe New England Journal of Medicine, 2006
- Recent time trends in acute myocardial infarction in Stockholm, SwedenInternational Journal of Cardiology, 2000